ARTELO BIOSCIENCES, INC.
Nasdaq · CIK 0001621221 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-2.7M
Net Income
$-3.0M
Eps Diluted
-4
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-2.7M | - | - |
| Net Income | $-3.0M | - | - |
| Eps Diluted | -4 | - | - |
| Cash And Equivalents | $10.3M | - | - |
| Total Assets | $12.5M | - | - |
| Total Liabilities | $5.8M | - | - |
| Shareholders Equity | $6.7M | - | - |
| Operating Cash Flow | $-1.2M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | ARTELO BIOSCIENCES, INC. | 2026-05-14 | 0001640334-26-000869 |
| 8-K | ARTELO BIOSCIENCES, INC. | 2026-03-17 | 0001640334-26-000461 |
| 10-K | ARTELO BIOSCIENCES, INC. | 2026-02-24 | 0001640334-26-000368 |
| 10-Q | ARTELO BIOSCIENCES, INC. | 2025-11-12 | 0001640334-25-002022 |
| 10-Q | ARTELO BIOSCIENCES, INC. | 2025-08-13 | 0001640334-25-001429 |